Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.
This patent grant is a significant milestone for Greenland Mines as it expands the geographic protection of its Klotho platform, which is central to the company’s biotech strategy. The KLTO-202 program aims to address ALS, a progressive neurodegenerative disease with limited treatment options. By securing patent rights in Australia, Greenland Mines can potentially develop and commercialize its therapy in that market, while also deterring competitors. The patent covers key aspects of the technology, including gene therapy constructs and delivery systems, which are critical for translating the platform into viable treatments.
The company’s biotech division is one of two operating segments, with the other being mining. Greenland Mines is focused on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. The company is also advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. However, the biotech division’s progress, particularly with the Klotho platform, represents a diversification into high-value therapeutic applications.
The Australian patent adds to Greenland Mines’ intellectual property portfolio, which is essential for attracting partners and investors. As the company advances KLTO-202, it may seek collaborations or additional funding to support clinical trials. The patent’s claims on delivery systems are particularly important, as effective delivery remains a challenge in gene therapy. By protecting both viral and non-viral methods, Greenland Mines secures flexibility in its approach.
For more details on the full press release, visit https://nnw.fm/PVbbH. Information about Greenland Mines and its latest updates can be found in the company’s newsroom at https://ibn.fm/GRML.
